American Society of Clinical Oncology (ASCO) 2014 Coverage

ASCO 2014

Breast Cancer Patients Concerned About Fertility

Exemestane + Ovarian Function Suppression Reduces Recurrence Risk in HR-Positive Early Breast Cancer

CHICAGO, IL—Adjuvant treatment with the aromatase inhibitor (AI) exemestane plus ovarian function suppression significantly reduced risk of disease recurrence in premenopausal women with hormone receptor (HR)-positive early breast cancer compared with tamoxifen plus ovarian function suppression (OFS), representing “a new treatment option for premenopausal women.”

Prostate-specific Antigen Screening: Still Debated

Safe to Postpone ADT in Men with Asymptomatic Prostate Cancer and Rising PSA Levels

CHICAGO, IL—For the approximately 60,000 men in the United States with prostate cancer who are asymptomatic after radical primary treatment yet have a prostate-specific antigen (PSA) relapse, it’s safe to postpone androgen deprivation therapy (ADT), an observational study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting concluded.

Next post in ASCO 2014